EUVIMEDEUVIMED entdecken
Crossref

Impact of GLP-1 Analogue Therapy on Gastrointestinal Outcomes in Patients with Irritable Bowel Syndrome: A Real-World TriNetX Analysis

Sajjad Ahmed Khan, Anurag Marasini, Alisha Shrestha, Hareesha Rishab Bharadwaj, Rahman Hameed Mohammed Abdul, Arkadeep Dhali, Saqr Alsakarneh, Ashish Sharma, Hassam Ali, Dushyant Singh Dahiya iD

Digestive Diseases and Sciences · 2026

DOI: 10.1007/s10620-026-10171-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive Diseases and Sciences, 2026. Verfasst von Sajjad Ahmed Khan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Birat Medical College Teaching Hospital, Morang, Nepal. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Glucagon-Like Peptide-1 Receptor Agonists, Glucagon-Like Peptide 1, Gastrointestinal Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly prescribed for diabetes and obesity, conditions that frequently coexist with irritable bowel syndrome (IBS). Their effects on gastrointestinal motility and visceral sensitivity raise the possibility of therapeutic benefit in IBS, but real-world evidence remains limited. This study evaluated the association between GLP-1 receptor agonist initiation and subsequent gastrointestinal outcomes in patients with IBS using a large federated electronic health records network. METHODS: We conducted a retrospective cohort study using the TriNetX Research Network. Patients with IBS (ICD-10 K58) who initiated GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) within 30 or 90 days after IBS diagnosis (GLP-1 group) were propensity score matched to IBS patients who did not receive GLP-1 therapy (non-GLP-1 group). Analyses were performed for the overall IBS cohort and stratified by subtype (IBS-D [K58.0] and IBS-C [K58.1]). Outcomes included coded chronic diarrhea, chronic constipation, abdominal pain, malabsorption, and abdominal bloating/distension. Incident outcomes were assessed using risk ratios, hazard ratios from Kaplan-Meier survival analysis, and log-rank tests. RESULTS: After matching, the 30-day landmark cohort included 4,668 patients per group and the 90-day landmark cohort included 6,665 patients per group. In the 90-day analysis, GLP-1 use was associated with significantly lower rates of chronic diarrhea (8.9% vs. 10.6%), chronic constipation (19.8% vs. 22.0%), abdominal pain (31.6% vs. 35.8%), and abdominal bloating/distension (8.3% vs. 10.9%) compared with non-GLP-1 controls (all p < 0.001). Similar reductions were observed in IBS-D and IBS-C subtypes, particularly for abdominal pain and bloating/distension. Differences in outcome recurrence (number of instances) were smaller than differences in incidence. CONCLUSIONS: Initiation of GLP-1 receptor agonists was associated with significantly lower rates of several coded gastrointestinal symptoms in patients with IBS across multiple landmark periods and subtypes. While these observational findings are hypothesis-generating and require confirmation in prospective studies, they suggest potential benefit of GLP-1 therapies on IBS-related outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Irritable Bowel SyndromeGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide 1Gastrointestinal AgentsHumansFemaleMaleRetrospective StudiesMiddle AgedAdultTirzepatideTreatment OutcomeExenatideSemaglutideLiraglutideDiarrheaGlucagon-Like PeptidesRecombinant Fusion ProteinsConstipationAbdominal PainImmunoglobulin Fc Fragments

Stichwörter der Autor:innen

GLP-1 analoguesGastrointestinal symptomsIrritable bowel syndromeReal-world evidence

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsTirzepatideExenatideSemaglutideGlucagon-Like Peptide 1LiraglutideGlucagon-Like PeptidesGastrointestinal AgentsdulaglutideRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Internal Medicine, Birat Medical College Teaching Hospital, Morang, Nepal.
  • Department of Internal Medicine, West Virginia University Health System, Princeton Community Hospital, Princeton, WV, USA.
  • Department of Internal Medicine, MedStar Georgetown University Hospital, Baltimore, USA.
  • Department of Internal Medicine, Royal Stoke University Hospital, University, Hospitals of North Midlands NHS, Stoke-On-Trent, Staffordshire, UK.
  • Department of Gastroenterology, Kings Mill Hospital, Sherwood Forest Hospitals NHS Foundation Trust, Nottinghamshire, UK.
  • Academic Unit of Gastroenterology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

ORCID-Profile: Dushyant Singh Dahiya

Zitieren

APA

Khan, S. A., Marasini, A., Shrestha, A., Bharadwaj, H. R., Abdul, R. H. M., Dhali, A., Alsakarneh, S., Sharma, A., Ali, H., & Dahiya, D. S. (2026). Impact of GLP-1 Analogue Therapy on Gastrointestinal Outcomes in Patients with Irritable Bowel Syndrome: A Real-World TriNetX Analysis. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-026-10171-w

Vancouver

Khan SA, Marasini A, Shrestha A, Bharadwaj HR, Abdul RHM, Dhali A, et al. Impact of GLP-1 Analogue Therapy on Gastrointestinal Outcomes in Patients with Irritable Bowel Syndrome: A Real-World TriNetX Analysis. Digestive Diseases and Sciences. 2026. doi:10.1007/s10620-026-10171-w

BibTeX
@article{Khan2026,
  author = {Khan, Sajjad Ahmed and Marasini, Anurag and Shrestha, Alisha and Bharadwaj, Hareesha Rishab and Abdul, Rahman Hameed Mohammed and Dhali, Arkadeep and Alsakarneh, Saqr and Sharma, Ashish and Ali, Hassam and Dahiya, Dushyant Singh},
  title = {Impact of GLP-1 Analogue Therapy on Gastrointestinal Outcomes in Patients with Irritable Bowel Syndrome: A Real-World TriNetX Analysis},
  journal = {Digestive Diseases and Sciences},
  year = {2026},
  doi = {10.1007/s10620-026-10171-w}
}
Kostenlos starten →